Current opinion in investigational drugs (London, England : 2000)

Curr Opin Investig Drugs · ISSN (print) 1472-4472 · 4 papers in corpus
review 2006
doi:10.1002/9783527623297.ch7 ·PMID:17086932

Since the discovery of the progesterone receptor antagonist mifepristone, numerous additional compounds, which display a spectrum of biological actions ranging from full antagonist to those with mixed agonist/antagonist activity, have been …

article 2003
·PMID:14649213

Endometriosis is an estrogen-dependent disorder mostly occurring in reproductive-age women. Various therapies have been used in an attempt to treat endometriosis, including ovarian suppression therapy, surgical treatment or a combination of…

review 2002
·PMID:12020064

Fulvestrant (Faslodex) is an estrogen receptor (ER) downregulator under development by AstraZeneca for the potential treatment of breast cancer [172191], [237518], [314472], [349551]. In March 2001, an NDA was filed in the US for the second…

review 2001
·PMID:11892935

Immunex has developed and launched etanercept, a soluble TNF receptor (TNFR) fusion protein, for the treatment of rheumatoid arthritis (RA). It has also been developed for various TNF-mediated conditions such as congestive heart failure, en…